Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first discussion titled Ketamine and Esketamine, is s-enantiomer of ketamine. Ketamine is a mixture of two enantiomers (mirror image molecules), for the treatment of depression in adults who have tried other antidepressant medicines .
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : Esketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clinically meaningful improvements in depression severity observed for Psilocybin (as measured by the MADRS1) with complete analysis of antidepressant efficacy and secondary outcomes pending.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific's team of researchers also continue to carry out multiple psychedelic-based clinical research trials.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Numerous clinical trials have demonstrated that IV ketamine has rapid and robust antidepressant effects in individuals who continue to suffer from depression, despite trying numerous antidepressant medications and psychotherapy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 04, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 14, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ketamine has been almost exclusively studied as an antidepressant adjunct to other antidepressants. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Brain and Cognition Discovery Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First multiple-dose psilocybin clinical trial will be conducted at Braxia Health's Canadian Rapid Treatment Centers. Trial will include adults with treatment-resistant depression and will also enroll adults who have previously tried electroconvulsive the...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Brain and Cognition Discovery Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Government of Canada
Deal Size : Undisclosed
Deal Type : Funding
Details : The fully funded study, representing the largest registered trial of its kind in the world, will investigate the use, safety and efficacy of repeated doses of intravenous (IV) Ketamine in patients with Bipolar Depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Government of Canada
Deal Size : Undisclosed
Deal Type : Funding